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Summary.-A retrospective survey has been made of58 patients with recurrent and
advanced male breast cancer treated with oral diethylstilboestrol. Fifty-five patients
were suitable for assessment. Fourteen patients had an objective response and 7 had
a partial response giving a total response of 21/55 patients (38%). The median
remission for the objective responders was 7 years. Three patients are alive and
free of disease; one has now been in remission for 13 years.
It is suggested that diethylstilboestrol is a useful treatment in patients with soft
tissue disease (breast, chest wall and/or lymph nodes).
IN VARIOUS reports (Haddow, Watkin-
son and Paterson, 1944; Treves, 1959;
Ogilvie, 1961) published on the treatment
of carcinoma of the male breast, opinions
differ as to the usefulness of stilboestrol
for the treatment of the recurrent and
advanced cases. Various types of oestro-
gens were used and too few patients were
treated, to be able to draw any conclusion
one way or the other. A more recent
series (Scheike, 1974) reported on 63
patients treated with stilboestrol, and the
conclusion was that it had " a reasonable
palliative effect (> 6 months) ". The
situation has been summed up by
Kennedy (1974), who stated that the
place of stilboestrol therapy in male
breast carcinoma was unknown. It is
felt that the present series might help
towards a more positive conclusion.
MATERIAL
Between January 1942 and January 1972,
205 cases of carcinoma of the male breast
were registered at the Christie Hospital and
Holt Radium Institute. Fifty-eight of the
205 patients were treated with diethyl-
stilboestrol. Twenty-seven had developed
recurrent disease following initial surgery,
17 patients had progressive disease following
radiotherapy and 14 patients had widespread
cancer at presentation (Clinical Stage IV).
None ofthe 58 patients had previous hormone
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or cytotoxic therapy prior to being put on
diethylstilboestrol.
Dosage.-The majority of patients in this
series were prescribed oral diethylstilboestrol
in a dosage of 15 mg/day (3 x 5 mg/day).
Two patients had 20 mg/day and 2 patients
had 3 mg/day (3 x 1 mg/day). All except
2 patients took the drug for at least 2 months.
Age.-The average age of the patients at
the time they were started on hormone
therapy, was 69 years. The youngest patient
was 33 years and the oldest was 88 years.
Response.-Tumour response was classi-
fied according to the criteria laid down by the
British Breast Group (1974).
RESULTS
Two patients stopped taking diethyl-
stilboestrol within one week due to
constant nausea and they are excluded
from the analysis. One patient was lost
to follow-up.
Table I shows the response obtained
by the 55 patients. Fourteen patients
had an objective response and 7 patients
had a partial response; the total response
being 21/55 (38%). The median remission
for those with an objective response was
7 years, and for the patients with a partial
response, one year. Three patients are
alive and free of disease; one has now
been in remission for 13 years.
Also shown in Table I is the medianG. G. RIBEIRO
TABLE I.-Response to Diethylstilboestrol
in 55 Patients
Medians*
Type of No. of
A
response patients Remission Survival 1 Survival 2
Objective 14 7 years 5 years 6 years
8 months 10 months
Partial 7 1 year 1 year 7 months
None 34 1 year 1 month
* Survival 1 includes 3 intercurrent deaths in the
group ofpatients with objective response; Survival 2
excludes the 3 deaths. There were no intercurrent
deaths in the groups of patients with partial or no
response.
survival ofthe 55 patients. Three patients
with objective responses died of inter-
current disease, two of myocardial infarc-
tion and one of chronic nephritis; there
was no evidence of cancer at death.
These 3 patients are included in Survival 1
for the objective responders giving a
median of 5 years 8 months and excluded
from Survival 2, which gives a median
of 6 years 10 months.
There were no intercurrent deaths
among the partial responders. All the
objective responses were obtained in the
patients who had their disease confined
to the soft tissues (breast, chest wall
and/or lymph nodes). All these patients
had previous irradiation to the site of the
primary and drainage areas, either fol-
lowing mastectomy or as the initial
treatment. When the disease recurred
or showed measurable progression, they
were then put on diethylstilboestrol.
Fourteen patients had multiple sites
involved and had hormone therapy as the
initial therapy but none of them
responded.
Two patients had lung and bone
metastases. Both had complete remission
of their lung metastases for 5 months, but
the remainder of the disease inevitably
progressed.
Six patients had bone metastases only.
None of them showed any response to
diethylstilboestrol.
Table II shows the comparison of the
type ofresponse in relation to the tumour-
free interval, i.e. the period between
primary treatment and the commence-
TABLE II.-Relation of Response to
Tumour-free Interval
Type ofresponse to stilboestrol
Tumour-free _ -A _
interval Objective Partial None
0-11 months 6 7 18
1 year- year
11 months
2 years +
Total
2 0 5
6 0 11
14 7 34
Total
31
7
17
55
ment of oestrogen therapy. The Table
does not suggest any relationship between
the length of time a patient is apparently
tumour-free and the type of response
obtained. However, it will be noted that
of the 7 patients with a partial response,
all had a tumour-free interval of less than
one year; the numbers of patients are too
small to regard this as statistically
significant.
If patients with tumour-free intervals
1 year-I year 11 months and 2 years+
are combined because of the small num-
bers, then the overall response (objective
and partial) is 8/24 (33%) compared to
13/31 (42%) with a tumour-free interval
of less than one year. This difference,
however, is not statistically significant.
Side effects
Very few side effects were noted. As
previously stated, 2 patients developed
constant nausea and they stopped taking
the drug within one week.
Two patients developed severe gynae-
comastia in the remaining breast, one
of the patients eventually stopping the
drug after 5 years. Neither of these
patients was given any irradiation to the
breast for relief from the gynaecomastia.
DISCUSSION
Kennedy and Kiang (1972) described
a case in which stilboestrol appeared to
have stimulated tumour growth in a male
patient with breast carcinoma. None of
the patients in this series showed this
phenomenon. Of the 2 patients on low-
dose stilboestrol (3 mg/day) one had
a partial response, and the other had no
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response. Since this series was looked at,
3 more patients have had low-dose
stilboestrol, with objective regression of
lung metastases in 2 ofthe 3 patients.
Treves (1959) reported on 14 of his
patients given various types ofoestrogens.
He claimed there was no response to
stilboestrol, but only 2 patients took the
hormone long enough. Two of 7 patients
who took ethinyloestradiol had a " favour-
able response ", but again the 5 non-
responders had not taken the hormone
for long enough.
In the same paper, Treves reported on
42 patients who underwent bilateral
orchidectomy. The objective response
rate was 28/42 (660o); however, 5 of these
patients were operable. Certainly there
was impressive regression of bone meta-
stases with relief of bone pain for long
periods, which was totally absent in this
present series.
Objective responses to adrenalectomy
in various series total up to 55%o (Li et al.,
1970) and following hypophysectomy 5 of
8 patients (62%) (Kennedy and Kiang,
1972) showed similar objective responses.
The numbers, even in the summated
series, are too small to draw valid con-
clusions.
The majority of patients in this series,
33 out of 55, had soft tissue disease. All
the objective remissions occurred in this
group of patients, with very few side
effects, a point of some importance when
one considers that the average age of the
series was 69 years. Further, in view of
the long periods of remission in these
patients, stilboestrol is a good alternative
to bilateral orchidectomy. However, in
view of the disappointing results of
stilboestrol in patients with bone meta-
stases, bilateral orchidectomy would
appear to be the best primary treatment
in this group.
My thanks are due to Dr A. W. Jackson
and Mr M. K. Palmer (Medical Statistician)
for valuable help in preparing this paper
and to Mrs Hurst, who typed the manu-
script.
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